Form 4: Moderna CFO's Equity Vesting and Tax Withholding

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of performance-based restricted stock units and subsequent tax-related share disposition.

Summary

• James M. Mock, Chief Financial Officer of Moderna, Inc. (MRNA), reported transactions related to his beneficial ownership.
• On February 11, 2026, 2,630 shares of Common Stock were acquired due to the vesting of performance-based restricted stock units (2023 PSUs) granted on February 28, 2023.
• Following this acquisition, Mr. Mock's beneficial ownership of Common Stock was 46,502 shares.
• Concurrently, 1,278 shares of Common Stock were disposed of at a price of $41.99 per share to satisfy tax withholding obligations related to the PSU vesting.
• After the disposition for tax purposes, Mr. Mock's beneficial ownership of Common Stock stands at 45,224 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard executive compensation transaction with no significant positive or negative implications for the company's operational or financial performance.

Positives

• The vesting of 2,630 performance-based restricted stock units indicates that performance targets set for the 2023 PSUs were met, reflecting positively on the company's operational achievements.

Negatives

• A disposition of 1,278 shares of Common Stock occurred to cover tax withholding obligations, resulting in a slight reduction in the reporting person's direct beneficial ownership.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider transactions like Form 4 filings for equity compensation vesting are common across the biotech and pharmaceutical industries, reflecting standard executive compensation structures designed to align management incentives with shareholder value.

Comparison to Industry Standards

• The structure of performance-based restricted stock units (PSUs) as a component of executive compensation is a widely adopted practice across the S&P 500 and particularly prevalent in high-growth sectors like biotechnology, similar to compensation packages observed at companies such as Pfizer, BioNTech, and Regeneron Pharmaceuticals.
• The practice of withholding shares to cover tax obligations upon vesting is a standard, efficient mechanism for executives to manage their tax liabilities, consistent with practices seen at peer companies.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-scheduled compensation event for an executive, not indicative of new strategic direction or financial performance.

Key Dates

Recommendation

This Form 4 reports a routine vesting of restricted stock units and subsequent tax withholding for a company executive, which does not provide new material information to alter an investment decision or change the fundamental outlook for Moderna.

Keywords

Moderna, MRNA, Form 4, Insider Transaction, Stock Vesting, Restricted Stock Units, CFO, Equity Compensation